Trials
Search / Trial NCT05640687

The Study of Mesenchymal Stem Cells Treat Autoimmune Pulmonary Alveolar Proteinosis in Vitro

Launched by GUANGZHOU INSTITUTE OF RESPIRATORY DISEASE · Nov 28, 2022

Trial Information

Current as of February 05, 2025

Unknown status

Keywords

A Pap Cell Therapy Msc

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Sign an informed consent form before any research-related activities;
  • 2. No gender restrictions, age ≥18 years old, and ≤75 years old;
  • 3. Patients who need to receive whole lung lavage due to the needs of the disease, and the patient agrees to perform whole lung lavage. The standards are as follows:
  • 1. The diagnosis of aPAP is clear, and the anti-GM-CSF antibody in serum is greater than 5 μg/ml;
  • 2. PaO2 \<65 mmHg;
  • 3. P(A-a)O2\>40 mmHg;
  • 4. Intrapulmonary shunt \>10%-12%.
  • Exclusion Criteria:
  • 1. Suffering from multiple chronic respiratory diseases at the same time, including but not limited to chronic obstructive pulmonary disease, pulmonary fibrosis, and asthma;
  • 2. Various malignant tumors or a history of malignant tumors;
  • 3. Uncontrolled pulmonary or systemic infection;
  • 4. Severe other systemic diseases: acute myocardial infarction, unstable angina pectoris, liver cirrhosis, acute glomerulonephritis, etc.;
  • 5. Syphilis, HIV, HCV antibody positive;
  • 6. Patients with coagulation disorders who cannot perform bronchoscopy, such as hemophilia, giant platelet syndrome, thrombocytopenia, etc.;
  • 7. Severe renal impairment, serum creatinine \> 1.5 times the upper limit of normal;
  • 8. Liver disease or liver function damage: ALT, AST, total bilirubin \> 2 times the upper limit of normal;
  • 9. Have any coexisting medical conditions or diseases that the investigators judge may impair the development of this trial;
  • 10. Social and mental disability, no legal capacity/limited capacity;
  • 11. Refuse to sign the informed consent.
  • -

About Guangzhou Institute Of Respiratory Disease

The Guangzhou Institute of Respiratory Disease is a leading research institution dedicated to advancing the understanding and treatment of respiratory diseases. With a strong focus on clinical trials, the Institute aims to develop innovative therapeutic strategies and improve patient outcomes through rigorous scientific inquiry. Committed to excellence in respiratory health, it collaborates with national and international partners to conduct cutting-edge research, fostering an environment of collaboration and knowledge exchange. The Institute plays a pivotal role in shaping respiratory medicine through its dedication to high-quality clinical research, training, and public health initiatives.

Locations

Guangzhou, Guangdong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials